KLK10 Antibody

說明書

中文名稱：

KLK10兔多克隆抗體
貨號：

CSB-PA012447ESR2HU
規格：

￥440
圖片：
Western blot
All lanes: KLK10 antibody at 1.48µg/ml + THP-1 whole cell lysate
Secondary
Goat polyclonal to rabbit IgG at 1/10000 dilution
Predicted band size: 30 kDa
Observed band size: 30 kDa

Immunohistochemistry of paraffin-embedded human prostate cancer using CSB-PA012447ESR2HU at dilution of 1:100

Immunohistochemistry of paraffin-embedded human pancreatic tissue using CSB-PA012447ESR2HU at dilution of 1:100
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品名稱：

Rabbit anti-Homo sapiens (Human) KLK10 Polyclonal antibody
Uniprot No.：

O43240
基因名：

KLK10
別名：

Breast normal epithelial cell associated serine protease antibody; Kallikrein related peptidase 10 antibody; Kallikrein-10 antibody; Kallikrein10 antibody; KLK 10 antibody; KLK10 antibody; KLK10_HUMAN antibody; NES 1 antibody; NES1 antibody; Normal epithelial cell specific 1 antibody; Normal epithelial cell-specific 1 antibody; Protease serine like 1 antibody; Protease serine-like 1 antibody; PRSS L1 antibody; PRSSL 1 antibody; PRSSL1 antibody
宿主：

Rabbit
反應種屬：

Human
免疫原：

Recombinant Human Kallikrein-10 protein (35-276AA)
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

Antigen Affinity Purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

PBS with 0.02% sodium azide, 50% glycerol, pH7.3.
產品提供形式：

Liquid
應用范圍：

ELISA, WB, IHC

推薦稀釋比：

Application	Recommended Dilution
WB	1:1000-1:5000
IHC	1:20-1:200

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Has a tumor-suppressor role for NES1 in breast and prostate cancer.
基因功能參考文獻：
1. MiR-199b-5p promotes cell proliferation, migration and suppresses apoptosis in cervical cancer cells. KLK10 is a direct target of miR-199b-5p. MiR-199b-5p expression is increased and positively correlated with KI-67 in human cervical cancer tissues and cell lines. PMID: 29807015
2. blockade of KLK10 attenuates epithelial-mesenchymal transition and activation of FAK-SRC-ERK signaling, which explains the mechanism of KLK10 in promoting metastasis. PMID: 29621546
3. To the best of our knowledge, this is the first report on KLK10 exon 3 unmethylated PCR product concentration as potential early epigenetic diagnostic marker in primary ovarian tumors. PMID: 29690914
4. KLK10 was verified to be a potential therapeutic target for reversing trastuzumab resistance in breast cancer cells. PMID: 27825132
5. Pronounced correlations between KLK10/KLK11 (rs = 0.647) and between KLK9/KLK15 (rs = 0.716) mRNA, but not between other combinations, indicate coordinate expression of distinct pairs of peptidases PMID: 29095848
6. identification and molecular cloning of eight novel transcripts of the human KLK10 gene using 3' rapid amplification of cDNA ends (3' RACE) and next-generation sequencing (NGS), as well as their expression analysis in a wide panel of cell lines, originating from several distinct cancerous and normal tissues PMID: 28419837
7. Data suggest that mature KLK9 (kallikrein 9) is a glycosylated chymotrypsin-like enzyme with strong preference for tyrosine over phenylalanine at P1 cleavage position; substrate specificity of KLK9 appears to extend to KLK10 and midkine; enzyme activity is enhanced by Mg2+ and Ca2+, but is reversibly attenuated by Zn2+; KLK9 is inhibited in vitro by many naturally occurring or synthetic protease inhibitors. PMID: 28559305
8. KLK10 potentially plays a crucial role in esophageal cancer cell growth. PMID: 26479703
9. KLK10 may function as a tumour suppressor by repressing proliferation, enhancing apoptosis and decreasing glucose metabolism in PC3 cells. PMID: 26616394
10. treated and untreated prolactin-producing pituitary adenomas and carcinomas as well as TSH-producing pituitary adenomas and carcinomas were conclusively immunopositive for KLK10 PMID: 25553760
11. Immunoexpression of KLK10 in the ACTH-secreting tumors as well as in the Crooke cell tumors was significantly increased when compared with the nonfunctioning tumors and in the corticotrophs of non-tumorous pituitaries. PMID: 25517869
12. is the first correlation of oral squamous cell carcinoma with KLK10 rs3745535G>T polymorphisms PMID: 23413953
13. KLK10 expression is an independent biomarker of unfavorable prognosis in patients with gastric cancer. PMID: 24409072
14. Patients with high KLK10 expression had a shorter disease-free and overall survival rates. PMID: 23499583
15. Enhancing KLK10 gene expression can decrease the proliferation and invasiveness of human tongue cancer cells in vitro. PMID: 23268413
16. Finding lower KLK10 levels in pleomorphic adenoma suggests aberrant expression in a tumour that develops primarily from myoepithelial cells. A kallikrein cascade may play a role in the development and/or outcome of some salivary gland tumours. PMID: 23250777
17. KLK10 DNA methylation was significantly associated with prostate cancer. PMID: 22874102
18. Data indicate a statistically significant positive association between kallikrein-related peptidase 10 (KLK10) and tumor stage and liver metastases. PMID: 22437349
19. Loss of KLK10 is associated with ovarian cancer. PMID: 22102857
20. KLK10 gene expression may be used as a marker of unfavorable prognosis for colorectal cancer PMID: 21487810
21. Single nucleotide polymorphisms in KLK10 is not associated with ovarian cancer. PMID: 20686372
22. Results indicate that cells underwent EMT exhibited overactive TGFbeta signaling and loss of expression of the CDH1, CGN, CLDN4, and KLK10 genes as a result of hypermethylation of their corresponding promoter regions. PMID: 20086175
23. NES1/kallikrein 10 mRNA is expressed in normal breast tissue and benign lesions, with loss of NES1/kallikrein 10 expression during tumor progression. PMID: 11705853
24. Identification of single nucleotide polymorphisms in the human kallikrein 10 (KLK10) gene and their association with prostate, breast, testicular, and ovarian cancers. PMID: 11920956
25. Higher expression in breast cancer predicts tamoxifen resistance PMID: 12087468
26. kallikrein 10 is expressed in the nonmalignant and malignant prostate, with cancer tissues demonstrating slightly lower expression PMID: 12970725
27. Downregulation of kallikrein 10 is associated with breast cancer PMID: 14696124
28. Kallikrein K10 is decreased in cerebrospinal fluid (CSF) of frontotemporal dementia patients and K10 is increased in CSF of Alzheimer patients, compared to control subjects. PMID: 14972646
29. new splice variants of the KLK10 gene identified; in silico analyses show differential expression of gene in various malignancies and provide basis for directing experimental efforts to investigate possible role of gene as cancer biomarker PMID: 16103744
30. CpG island hypermethylation plays an important role in the downregulation of kallikrein 10 mRNA and protein expression PMID: 16254462
31. Kallikrein 10 is highly expressed in uterine serous papillary carcinoma, and it is released in the plasma and serum of uterine serous papillary carcinoma patients. PMID: 16647913
32. REVIEW of KLK10 gene expression in neoplasm cells PMID: 16800732
33. functional importance of retinoic acid response elements in the hK10 promoter was demonstrated by retinoid induction of hk10 promoter-reporters PMID: 16800735
34. results suggest a co-regulation of KLK10 and KLK11 expression in lung and a lack of KLK10 suppressor role in non-small-cell lung cancer PMID: 16800740
35. KLK10 expression is up-regulated in CRC and GC and higher expression of KLK10 closely correlates with advanced disease stage, which predicts a poorer prognosis. PMID: 16928223
36. Results suggest that NES1 inactivation might contribute to the malignant progression of human gastric cancers. PMID: 17182177
37. Glucocorticoid receptor-mediated expression of kallikrein 10 PMID: 17937626
38. The hormone-specific upregulation of PSA, KLK10 and KLK11 in the breast cancer cell line T47D is dependent on major intracellular signaling pathways. PMID: 18515984
39. Suppression of gastric cancer growth by baculovirus vector-mediated transfer of normal epithelial cell specific-1 gene. PMID: 18855978
40. synergistic effects between estrogens and androgens on estrogen-sensitive genes may have implications on the role of the kallikreins 10, 11, and 14 in associated risk of breast cancer and progression. PMID: 19383315
41. Down-Regulation of KLK10 through DNA Methylation is associated with hepatocellular carcinoma. PMID: 19760608
顯示更多

收起更多
亞細胞定位：

Secreted.
蛋白家族：

Peptidase S1 family, Kallikrein subfamily
組織特異性：

Expressed in breast, ovary and prostate.
數據庫鏈接：

HGNC: 6358

OMIM: 602673

KEGG: hsa:5655

STRING: 9606.ENSP00000311746

UniGene: Hs.275464

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human